File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Telbivudine for chronic hepatitis B: The GLOBE trial

TitleTelbivudine for chronic hepatitis B: The GLOBE trial
Authors
KeywordsALT normalization
GLOBE trial
HBeAg loss
HBeAg negative
HBeAg positive
HBeAg seroconversion
HBV DNA levels
Lamivudine
Telbivudine
Viral resistance
Issue Date2008
PublisherFuture Medicine Ltd. The Journal's web site is located at http://www.futuremedicine.com/loi/fvl
Citation
Future Virology, 2008, v. 3 n. 4, p. 317-323 How to Cite?
AbstractTelbivudine is the latest nucleoside/nucleotide analog approved for the treatment of chronic hepatitis B. It has been extensively studied in Phase I, II and III trials. The Phase III trial (the GLOBE study) recruited more than 1300 chronic hepatitis B patients. It demonstrated that telbivudine was superior to lamivudine with a greater reduction of HBV DNA levels in hepatitis B e antigen (HBeAg)-positive and -negative disease after 1 year of treatment. The resistance rate at year 1 was also lower in patients receiving telbivudine. This antiviral superiority is maintained up to 2 years of treatment. There were no serious adverse effects in patients receiving telbivudine treatment. To further minimize the chance of emergence of drug resistance, careful patient selection according to the baseline HBV DNA levels, alanine aminotransferase levels and HBV DNA levels at week 24 of treatment should be carried out. Continuation of telbivudine monotherapy is associated with a low chance of resistance patients receiving telbivudine who have undetectable HBV DNA levels at week 24. © 2008 Future Medicine Ltd.
Persistent Identifierhttp://hdl.handle.net/10722/59208
ISSN
2015 Impact Factor: 0.886
2015 SCImago Journal Rankings: 0.529
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorYuen, MFen_HK
dc.contributor.authorLai, CLen_HK
dc.date.accessioned2010-05-31T03:45:08Z-
dc.date.available2010-05-31T03:45:08Z-
dc.date.issued2008en_HK
dc.identifier.citationFuture Virology, 2008, v. 3 n. 4, p. 317-323en_HK
dc.identifier.issn1746-0794en_HK
dc.identifier.urihttp://hdl.handle.net/10722/59208-
dc.description.abstractTelbivudine is the latest nucleoside/nucleotide analog approved for the treatment of chronic hepatitis B. It has been extensively studied in Phase I, II and III trials. The Phase III trial (the GLOBE study) recruited more than 1300 chronic hepatitis B patients. It demonstrated that telbivudine was superior to lamivudine with a greater reduction of HBV DNA levels in hepatitis B e antigen (HBeAg)-positive and -negative disease after 1 year of treatment. The resistance rate at year 1 was also lower in patients receiving telbivudine. This antiviral superiority is maintained up to 2 years of treatment. There were no serious adverse effects in patients receiving telbivudine treatment. To further minimize the chance of emergence of drug resistance, careful patient selection according to the baseline HBV DNA levels, alanine aminotransferase levels and HBV DNA levels at week 24 of treatment should be carried out. Continuation of telbivudine monotherapy is associated with a low chance of resistance patients receiving telbivudine who have undetectable HBV DNA levels at week 24. © 2008 Future Medicine Ltd.en_HK
dc.languageengen_HK
dc.publisherFuture Medicine Ltd. The Journal's web site is located at http://www.futuremedicine.com/loi/fvlen_HK
dc.relation.ispartofFuture Virologyen_HK
dc.subjectALT normalizationen_HK
dc.subjectGLOBE trialen_HK
dc.subjectHBeAg lossen_HK
dc.subjectHBeAg negativeen_HK
dc.subjectHBeAg positiveen_HK
dc.subjectHBeAg seroconversionen_HK
dc.subjectHBV DNA levelsen_HK
dc.subjectLamivudineen_HK
dc.subjectTelbivudineen_HK
dc.subjectViral resistanceen_HK
dc.titleTelbivudine for chronic hepatitis B: The GLOBE trialen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=1746-0794&volume=3&issue=4&spage=317&epage=323&date=2008&atitle=Telbivudine+for+chronic+hepatitis+B:+The+GLOBE+trial.en_HK
dc.identifier.emailYuen, MF:mfyuen@hkucc.hku.hken_HK
dc.identifier.emailLai, CL:hrmelcl@hku.hken_HK
dc.identifier.authorityYuen, MF=rp00479en_HK
dc.identifier.authorityLai, CL=rp00314en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.2217/17460794.3.4.317en_HK
dc.identifier.scopuseid_2-s2.0-55849121225en_HK
dc.identifier.hkuros161004en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-55849121225&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume3en_HK
dc.identifier.issue4en_HK
dc.identifier.spage317en_HK
dc.identifier.epage323en_HK
dc.identifier.isiWOS:000258548100009-
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridYuen, MF=7102031955en_HK
dc.identifier.scopusauthoridLai, CL=7403086396en_HK
dc.identifier.citeulike3094769-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats